ArticleCost effectiveness and resource allocation : C/E2021
Medical expenditure for lung cancer in China: a multicenter, hospital-based retrospective survey.
Article in Cost effectiveness and resource allocation : C/E, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Cost of managing brain metastases in ALK-positive advanced NSCLC patients receiving first-line ALK TKIs in China.Lung cancer management · 2026Article
- Cost-effectiveness of hypofractionated radiation therapy versus conventional radiation therapy for unresectable stage III non-small cell lung cancer.Scientific reports · 2025Article
- Cost effectiveness analysis of low dose computed tomography lung cancer screening in Chinese population.Scientific reports · 2025Article
- Holistic Influence of Multimodal Medical Crowdfunding Affordances on Charitable Crowdfunding Outcome: Systematic Multimodel Analysis Study.JMIR medical informatics · 2025Article
- Preferences for public health insurance coverage of new anticancer drugs: a discrete choice experiment among non-small cell lung cancer patients in China.BMC public health · 2025Article
- Pharmacoeconomic evaluation of weight-based vs fixed-dose pembrolizumab for non-small cell lung cancer in China.Frontiers in immunology · 2025Article
- Cost Shifting in Lung Cancer Inpatient Care Under Diagnosis-Intervention Packet Reform: A Pilot Study in China.Risk management and healthcare policy · 2025Article
- Article
- Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Societal Perspective.Advances in therapy · 2024Article
- Cost-effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer.Future oncology (London, England) · 2024Article
- Evolutionary game analysis of indoor radon mitigation with local government involvement.Heliyon · 2023Article
- Survival differences between the USA and an urban population from China for all cancer types and 20 individual cancers: a population-based study.The Lancet regional health. Western Pacific · 2023Article
- Observational
- Lung Cancer-Specific Mortality Risk and Public Health Insurance: A Prospective Cohort Study in Chongqing, Southwest China.Frontiers in public health · 2022Article
- Catastrophic health expenditure and its determinants in households with lung cancer patients in China: a retrospective cohort study.BMC cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
Abstract
backgroundLung cancer is the most prevalent cancer, and the leading cause of cancer-related deaths in China. The aim of this study was to estimate the direct medical expenditure incurred for lung cancer care and analyze the trend therein for the period 2002-2011 using nationally representative data in China
methodsThis study was based on 10-year, multicenter retrospective expenditure data collected from hospital records, covering 15,437 lung cancer patients from 13 provinces diagnosed during the period 2002-2011. All expenditure data were adjusted to 2011 to eliminate the effects of inflation using China's annual consumer price index.
resultsThe direct medical expenditure for lung cancer care (in 2011) was 39,015 CNY (US$6,041) per case, with an annual growth rate of 7.55% from 2002 to 2011. Drug costs were the highest proportionally in the total medical expenditure (54.27%), followed by treatment expenditure (14.32%) and surgical expenditure (8.10%). Medical expenditures for the disease varied based on region, hospital level, type, and stage.
conclusionThe medical expenditure for lung cancer care is substantial in China. Drug costs and laboratory test are the main factors increasing medical costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.